CD274 and neoplasm: [45] In lung adenocarcinomas PD-L1 IHC positivity is a pre-requisite for certain immune checkpoint inhibitor treatment, but for CRC, MMR status, acting as a surrogate for tumor mutational burden, is the preferred predictive biomarker as discussed above.